LU90311I2 - Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci - Google Patents

Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci

Info

Publication number
LU90311I2
LU90311I2 LU90311C LU90311C LU90311I2 LU 90311 I2 LU90311 I2 LU 90311I2 LU 90311 C LU90311 C LU 90311C LU 90311 C LU90311 C LU 90311C LU 90311 I2 LU90311 I2 LU 90311I2
Authority
LU
Luxembourg
Prior art keywords
amino acid
precursors
prodrugs
alatrofloxacin
trovafloxacin
Prior art date
Application number
LU90311C
Other languages
English (en)
Inventor
Katherine Elizabeth Brighty
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of LU90311I2 publication Critical patent/LU90311I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU90311C 1989-08-16 1998-11-04 Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci LU90311I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1989/003489 WO1991002526A1 (fr) 1989-08-16 1989-08-16 Acides azabicyclo quinolone carboxyliques

Publications (1)

Publication Number Publication Date
LU90311I2 true LU90311I2 (fr) 1999-01-25

Family

ID=22215165

Family Applications (2)

Application Number Title Priority Date Filing Date
LU90310C LU90310I2 (fr) 1989-08-16 1998-11-04 Trovafloxacine et ses sels pharmaceutiquement acceptables en particulier le sel mésylate de celui-ci et les précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en parti
LU90311C LU90311I2 (fr) 1989-08-16 1998-11-04 Précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en particulier le sel mésylate de celui-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU90310C LU90310I2 (fr) 1989-08-16 1998-11-04 Trovafloxacine et ses sels pharmaceutiquement acceptables en particulier le sel mésylate de celui-ci et les précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en parti

Country Status (30)

Country Link
EP (1) EP0413455B1 (fr)
JP (2) JPH072734B2 (fr)
KR (1) KR930004844B1 (fr)
CN (1) CN1025192C (fr)
AT (1) ATE124040T1 (fr)
AU (1) AU623801B2 (fr)
BA (1) BA98299A (fr)
CA (2) CA2127561C (fr)
CY (2) CY1969A (fr)
CZ (1) CZ281127B6 (fr)
DD (1) DD298399A5 (fr)
DE (3) DE19875050I2 (fr)
DK (1) DK0413455T3 (fr)
EG (1) EG19251A (fr)
ES (1) ES2074131T4 (fr)
FI (2) FI108228B (fr)
GR (1) GR3017072T3 (fr)
HK (1) HK1000207A1 (fr)
HU (2) HU219403B (fr)
IE (1) IE66202B1 (fr)
IL (1) IL95331A (fr)
LU (2) LU90310I2 (fr)
NL (2) NL980032I2 (fr)
NO (1) NO300214B1 (fr)
NZ (1) NZ234920A (fr)
PL (1) PL166381B1 (fr)
PT (1) PT94998B (fr)
RU (1) RU2049777C1 (fr)
WO (1) WO1991002526A1 (fr)
ZA (1) ZA906450B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449445A3 (en) * 1990-03-27 1993-08-25 Pfizer Inc. Preparation of beta-ketoesters useful in preparing quinolone antibiotics
FR2675144B1 (fr) * 1991-04-10 1995-06-16 Bouchara Sa Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant.
CA2111463C (fr) * 1991-06-19 1997-08-26 Bingwei V. Yang Agents antibacteriens azaspiro quinolone
US5256791A (en) * 1992-03-02 1993-10-26 Pfizer Inc. Preparation of intermediates in the synthesis of quinoline antibiotics
EG20543A (en) * 1992-10-30 1999-07-31 Procter & Gamble Process for preparing of novel antimicrobial -5- (n-heterosubstituted amino) quinolones
US5527910A (en) * 1992-12-30 1996-06-18 Cheil Foods & Chemicals, Inc. Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria
US5591766A (en) * 1993-12-03 1997-01-07 Cheil Foods & Chemicals, Inc. Solid oral formulations of pyridone carboxylic acids
PT812838E (pt) * 1994-02-04 2002-10-31 Dainippon Pharmaceutical Co Derivado de acido piridonacarboxilico substituido com o grupo amino biciclico seu ester seu sal e amina biciclica como seu intermediario
PT807630E (pt) * 1995-02-02 2003-08-29 Daiichi Seiyaku Co Compostos heterociclicos
JPH08213881A (ja) * 1995-02-02 1996-08-20 Fujitsu Ltd 周波数制御回路
WO1996024593A1 (fr) * 1995-02-07 1996-08-15 Daiichi Pharmaceutical Co., Ltd. Derives spiro heterocycliques
DE69503066T2 (de) * 1995-06-06 1998-10-15 Pfizer Inc., New York, N.Y. KRISTALLFORM VON WASSERFREIEN 7-((1a,5a,6a)-6-AMINO-3-AZABICYCLO (3.1.0.) HEX-3-YL)-6-FLUORO-1-(2,4-DIFLUOROPHENYL)-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDIN-CARBONSÄURE METHANESULFONSÄURE SALZ
DE69622715T2 (de) * 1995-06-15 2002-11-14 Pfizer Inc., New York Verfahren zur herstellung von derivaten der ein peptid enthaltenden azabizylo-naphtyridin-carbonsäure
KR100276477B1 (ko) * 1996-02-09 2000-12-15 나카노 가쓰히코 퀴놀론카복실산유도체또는그의염
AP788A (en) * 1996-08-26 1999-12-03 Pfizer Novel crystal form of anhydrous 7-(1a, 5a, 6a)-6-Amino-3-Azabicyclo(3.1.0) hex-3-YI)-6-Fluoro-1-(2,4- Difluorophenyl)-1,4-Dihydro-4-Oxo-1, 8-Naphthyridine-3-Carboxylic Acid, Methanesulfonic acid salt.
TW519542B (en) * 1996-09-27 2003-02-01 Daiichi Seiyaku Co Bicyclic amine derivative
ATE267191T1 (de) 1996-10-25 2004-06-15 Daiichi Seiyaku Co Tricyclische aminderivate
US20020032216A1 (en) 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
MA24500A1 (fr) 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
DE19733439A1 (de) * 1997-08-02 1999-02-04 Bayer Ag Neue 6-endo-Amino-3-azabicyclo(3.1.0)hexande, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung von Chinolon- und Naphthyridincarbonsäure-Derviaten mit verbesserten Eigenschaften
CN1264837C (zh) 1997-09-15 2006-07-19 普罗克特和甘保尔公司 喹诺酮抗微生物剂、其组合物和应用
US6184380B1 (en) * 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
PA8464701A1 (es) * 1998-01-16 2000-09-29 Pfizer Prod Inc Procedimiento e intermedios para preparar naftiridonas
US7019142B2 (en) 1998-01-16 2006-03-28 Pfizer Inc. Process for preparing naphthyridones and intermediates
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
HK1044476B (zh) 1999-03-17 2010-09-17 第一制药株式会社 药物组合物
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
ATE304539T1 (de) 2000-12-14 2005-09-15 Procter & Gamble Antimikrobielle chinolone
AU2002230893B2 (en) 2000-12-14 2005-06-09 The Procter & Gamble Company Antimicrobial 2-pyridones, their compositions and uses
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EA200500173A1 (ru) 2002-07-08 2005-08-25 Рэнбакси Лабораториз Лимитед Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
EP1534675B1 (fr) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
EP1615634B1 (fr) 2003-04-10 2007-05-16 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane en tant qu'antagonistes des recepteurs muscariniques
WO2004089900A1 (fr) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Derives azabicyclo utiles comme antagonistes du recepteur muscarinique
PL1666477T3 (pl) 2003-09-10 2013-11-29 Kyorin Seiyaku Kk Pochodna kwasu 7-(4-podstawionego-3-cyklopropyloaminometylo-1- pirolidynylo)chinolonokarboksylowego
WO2005026121A1 (fr) * 2003-09-18 2005-03-24 Ranbaxy Laboratories Limited Procede de preparation de (1$g(a), 5$g(a), 6$g(a))-6-aminomethyl-3-benzyl-3-azabicyclo[3.1.0]hexane
TWI391378B (zh) * 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
CA2647454A1 (fr) 2006-03-28 2007-10-04 The Procter & Gamble Company Procede de couplage pour preparer des intermediaires quinolone
ES2366150T3 (es) 2006-03-28 2011-10-17 Warner Chilcott Company, Llc Malatos de polimorfos de ácido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolinocarboxílico.
US7902227B2 (en) * 2007-07-27 2011-03-08 Janssen Pharmaceutica Nv. C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
US12421210B2 (en) * 2018-10-05 2025-09-23 New York University Fused bicyclic heterocycles as therapeutic agents
CN112442084B (zh) * 2020-12-03 2022-09-09 国药集团致君(深圳)制药有限公司 一种抗菌药中间体的制备方法
CN113307768B (zh) * 2021-04-29 2023-12-12 中国农业科学院兰州畜牧与兽药研究所 喹诺酮类衍生物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676400B2 (ja) * 1987-08-25 1994-09-28 大日本製薬株式会社 新規ピリドンカルボン酸誘導体、そのエステルおよびその塩
JP2844079B2 (ja) * 1988-05-23 1999-01-06 塩野義製薬株式会社 ピリドンカルボン酸系抗菌剤
US4973091A (en) * 1989-09-20 1990-11-27 Truth Incorporated Sliding patio door dual point latch and lock

Also Published As

Publication number Publication date
FI964520A0 (fi) 1996-11-11
DE19875052I2 (de) 2009-05-28
HU211681A9 (en) 1995-12-28
CY99010I2 (en) 2010-07-28
HU219403B (hu) 2001-04-28
FI920632A0 (fi) 1992-02-14
NO920599L (no) 1992-04-14
PT94998B (pt) 1997-05-28
KR910004572A (ko) 1991-03-28
NO920599D0 (no) 1992-02-14
KR930004844B1 (ko) 1993-06-09
NL980033I2 (nl) 1999-05-03
EP0413455A2 (fr) 1991-02-20
FI103879B1 (fi) 1999-10-15
BA98299A (bs) 2001-09-14
EP0413455A3 (en) 1991-10-09
PL286484A1 (en) 1991-05-20
DE69020262D1 (de) 1995-07-27
DE19875050I2 (de) 2009-05-28
ZA906450B (en) 1992-03-25
CA2127561C (fr) 1998-07-28
FI964520L (fi) 1996-11-11
WO1991002526A1 (fr) 1991-03-07
IL95331A (en) 1995-07-31
AU623801B2 (en) 1992-05-21
FI108228B (fi) 2001-12-14
PL166381B1 (pl) 1995-05-31
EP0413455B1 (fr) 1995-06-21
HK1000207A1 (en) 1998-02-06
AU6104290A (en) 1991-02-21
NL980032I2 (nl) 1999-05-03
CN1025192C (zh) 1994-06-29
NZ234920A (en) 1992-06-25
JPH0386875A (ja) 1991-04-11
CN1049501A (zh) 1991-02-27
NL980033I1 (nl) 1999-02-01
IE66202B1 (en) 1995-12-13
JPH072734B2 (ja) 1995-01-18
CZ402790A3 (en) 1996-04-17
IE902950A1 (en) 1991-02-27
CZ281127B6 (cs) 1996-06-12
CA2023217A1 (fr) 1991-02-17
ATE124040T1 (de) 1995-07-15
NO300214B1 (no) 1997-04-28
NL980032I1 (nl) 1999-02-01
DD298399A5 (de) 1992-02-20
ES2074131T3 (es) 1995-09-01
CA2127561A1 (fr) 1991-02-17
ES2074131T4 (es) 1996-05-01
JPH07149758A (ja) 1995-06-13
LU90310I2 (fr) 1999-01-25
GR3017072T3 (en) 1995-11-30
RU2049777C1 (ru) 1995-12-10
CY1969A (en) 1997-09-05
EG19251A (en) 1994-09-29
DE69020262T2 (de) 1995-10-26
PT94998A (pt) 1991-04-18
CA2023217C (fr) 1996-12-10
DK0413455T3 (da) 1995-08-14
JPH0819099B2 (ja) 1996-02-28
IL95331A0 (en) 1991-06-30
FI103879B (fi) 1999-10-15

Similar Documents

Publication Publication Date Title
LU90310I2 (fr) Trovafloxacine et ses sels pharmaceutiquement acceptables en particulier le sel mésylate de celui-ci et les précurseurs de médicament (prodrogues) de la trovafloxacine ayant des groupes d'acides aminés libres ces précurseurs comprenant un résidu d'acide aminé ou une chaîne de polypeptides de deux ou plusieurs résidus d'acides aminés qui sont liés de manière covalente par des liaisons peptidiques incluant l'alatrofloxacine optionnellement sous forme d'un sel pharmaceutiquement acceptable en parti
RU2000111540A (ru) Агонисты аполипопротеина а-1 и их применение для лечения заболеваний, связанных с дислипидемией
KR950701937A (ko) 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체(glucagon-like peptide and insulinotropin derivatives)
ES8105698A1 (es) Procedimiento para la obtencion de octapeptidos ciclicos
KR970042553A (ko) 캠프토테신 유도체
EP0299402A3 (en) Lhrh antagonists, their manufacture and pharmaceutical clhrh antagonists, their manufacture and pharmaceutical compositions thereof ompositions thereof
EE02950B1 (et) Metüleenbisfosfoonhappe esteramiidderivaadid, meetod nende valmistamiseks ja farmatseutiline kompositsioon
HU9301520D0 (en) Methods for producing cyclopeptides promoting absorption of peptides and albumins through mucous membrane as well as pharmaceutical preparations containing said compounds as auxiliary agents
CA2215827A1 (fr) Composes a base d'o-malonyltyrosyle, peptides contenant des composes a base d'o-malonyltyrosyle et leurs utilisations
KR900009692A (ko) 레트로바이러스 프로테아제 억제제
JP2002522508A5 (fr)
JPH09124692A5 (fr)
EP0346068A3 (fr) Antagonistes de D-Cys6-vasopressine
JPH11514858A (ja) 骨刺激因子
NZ822560A (en) Novel triple glp-1/gip/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same
US6218364B1 (en) Fluorinated neurokinin A antagonists
HUT59919A (en) Process for producing azabicyclo-quinolon and naphtiridone derivatives and pharmaceutical compositions containing them
KR890013058A (ko) 아미노산 유도체
RU2008129731A (ru) Новые пептиды-т-хелперные антигенные детерминанты (thd)
SI9300595B (sl) Peptidi z organo-protektivno aktivnostjo, postopki za njihovo pripravo in njihova uporaba v terapiji
ES2005778A6 (es) Procedimiento para la obtencion de derivados de diisobutilxantina.
RU98117609A (ru) Пептидные производные
RU97112094A (ru) Ингибиторы фибронектиновой адгезии